💎 Fed’s first rate cut since 2020 set to trigger market. Find undervalued gems with Fair ValueSee Undervalued Stocks

Inovio Pharma secures $56M in funding for Lassa fever and MERS vaccines; shares up 6% premarket

Published 04/11/2018, 09:19 AM
© Reuters.  Inovio Pharma secures $56M in funding for Lassa fever and MERS vaccines; shares up 6% premarket
INO
-
  • Inovio Pharmaceuticals (NYSEMKT:INO) is up 6% premarket on average volume on the heels of its announcement that the Coalition for Epidemic Preparedness Innovations (CEPI) will provide up the $56M in funding to support the development of vaccines against Lassa fever (INO-4500) and Middle East Respiratory Syndrome (MERS) (INO-4700) through Phase 2.
  • The agreement, providing funding over a five-year period, also includes options to establish investigational stockpiles of both vaccines.
  • CEPI is a partnership between public, private, philanthropic and civil organizations founded in Davos last year.
  • Previously: GeoVax awarded NIH grant to support development of Lassa virus vaccine; shares up 8% (April 10)
  • Now read: Inovio's China Partnership License Agreement Should Be Cheered


Original article

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.